Shilpa Medicare Limited, a pharmaceutical company based in India, has recently received Good Manufacturing Practice (GMP) certification for two of its manufacturing facilities in Telangana from the Eurasian Economic Union (EAEU). This certification will allow the company to expand its business operations in Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia – the member countries of the economic union.
The certified facilities include Unit IV in Jadcherla, which produces sterile injectable and non-sterile oral dosage forms, and Unit VII in Nacharam, Hyderabad, which focuses on testing activities for raw materials, packing materials, and finished dosage forms. This approval was granted after inspections by Belarus’s Ministry of Health in October 2024.
Shilpa Medicare operates as an integrated pharmaceutical group with a specialization in oncology and non-oncology APIs, peptides, polymers, and differentiated finished dosage formulations. The company also offers Contract Development and Manufacturing Organization (CDMO) services to global pharmaceutical companies through its network of R&D units and manufacturing facilities.
This development is a significant step in Shilpa Medicare’s international market expansion strategy, particularly in the EAEU region. The company’s portfolio includes orally dispersible films, transdermal patches, and biological products.
Overall, the EAEU GMP certification highlights Shilpa Medicare’s commitment to maintaining high-quality standards in its manufacturing processes and opens up new opportunities for growth and collaboration in the international pharmaceutical market.
